Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY

Key Points

• Korea Investment CORP boosted its stake in Incyte by 190.2% in Q3 to 229,326 shares, worth about $19.45M (≈0.12% of the company).
• Incyte reported quarterly EPS of $1.80, missing the $1.96 estimate, while revenue was $1.51B (above the $1.35B estimate) and rose 27.8% year‑over‑year.
• Insiders sold a total of 72,561 shares (≈$7.2M) over the past 90 days, though insiders still own 17.8% and institutional investors hold about 96.97% of the stock.

Korea Investment CORP increased its position in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 190.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 229,326 shares of the biopharmaceutical company's stock after acquiring an additional 150,300 shares during the quarter. Korea Investment CORP owned about 0.12% of Incyte worth $19,449,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. purchased a new position in Incyte in the third quarter worth $26,000. Root Financial Partners LLC acquired a new position in shares of Incyte during the third quarter worth $28,000. Quent Capital LLC purchased a new stake in shares of Incyte during the 3rd quarter valued at $30,000. MUFG Securities EMEA plc purchased a new stake in shares of Incyte during the 2nd quarter valued at $32,000. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Incyte in the 2nd quarter worth $33,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Incyte news, insider Thomas Tray sold 2,774 shares of Incyte stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the transaction, the insider owned 22,973 shares in the company, valued at approximately $2,297,300. This trade represents a 10.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the transaction, the executive vice president directly owned 66,132 shares of the company's stock, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 72,561 shares of company stock valued at $7,195,307 over the last 90 days. Insiders own 17.80% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on INCY shares. Weiss Ratings raised Incyte from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday, March 2nd. Wells Fargo & Company decreased their price target on Incyte from $107.00 to $101.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 11th. Royal Bank Of Canada dropped their price target on Incyte from $95.00 to $92.00 and set a "sector perform" rating on the stock in a research note on Wednesday, February 11th. The Goldman Sachs Group restated a "neutral" rating and set a $90.00 price objective on shares of Incyte in a report on Thursday, January 8th. Finally, Stifel Nicolaus increased their price objective on shares of Incyte from $119.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Ten equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $104.00.

Incyte Trading Down 1.1%

Incyte stock opened at $96.02 on Wednesday. The stock has a 50-day moving average price of $102.18 and a 200 day moving average price of $96.47. The company has a market capitalization of $19.11 billion, a price-to-earnings ratio of 14.98, a price-to-earnings-growth ratio of 0.77 and a beta of 0.84. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $112.29. The company has a quick ratio of 3.25, a current ratio of 3.32 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same quarter last year, the company posted $1.43 EPS. Incyte's quarterly revenue was up 27.8% compared to the same quarter last year. Sell-side analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.